Aurobindo Pharma shares in focus on Monday after US FDA inspection concludes with five observations

Aurobindo Pharma is expected to remain in focus on Monday after the company disclosed that its stepdown subsidiary, Eugia Steriles Private Limited, received five observations from the United States Food and Drug Administration (US FDA) following a pre-approval inspection.

According to the company's regulatory filing, the US FDA conducted the inspection at Eugia Steriles’ manufacturing facility located in Parawada Mandal, Anakapalli District, Andhra Pradesh, from June 10 to June 19, 2026. The inspection concluded with the issuance of five observations.

The inspection forms part of the US FDA's pre-approval process, which assesses whether manufacturing facilities meet the required quality and compliance standards before products receive regulatory approval for the US market.

Aurobindo Pharma stated that it will address the observations within the stipulated timeframe and remains committed to maintaining high-quality manufacturing standards across its global operations.

Importantly, the company clarified that the observations are not expected to have any impact on its financial performance or business operations. Aurobindo Pharma also assured investors and stakeholders that it will continue to keep stock exchanges informed of any material developments related to the matter.

Eugia Steriles Private Limited is a wholly owned subsidiary of Eugia Pharma Specialities Limited, which itself is a stepdown subsidiary of Aurobindo Pharma. The facility plays a key role in the group's sterile pharmaceutical manufacturing operations.